Valuation: Veradermics, Incorporated

Market Cap 5.22B 4.57B 4.22B 3.9B 7.39B 498B 7.51B 50.38B 19.73B 245B 19.59B 19.17B 844B P/E 2026 *
-42.5x
P/E 2027 * -46.1x
Enterprise Value 5.22B 4.57B 4.22B 3.9B 7.39B 498B 7.51B 50.38B 19.73B 245B 19.59B 19.17B 844B EV / Sales 2026 *
-
EV / Sales 2027 * 502x
Free-Float
97.26%
Yield 2026 *
-
Yield 2027 * -
1 day-4.25%
1 week-2.02%
Current month-2.72%
1 month+28.63%
3 months+73.84%
1 week 116.19
Extreme 116.19
129.8
1 month 86.83
Extreme 86.83
131.24
Current year 32
Extreme 32
131.24
1 year 32
Extreme 32
131.24
3 years 32
Extreme 32
131.24
5 years 32
Extreme 32
131.24
10 years 32
Extreme 32
131.24
Manager TitleAgeSince
Chief Executive Officer 31 2022-11-30
President 36 2020-07-31
Director of Finance/CFO 40 2023-09-30
Director TitleAgeSince
Director/Board Member 31 2019-09-30
Director/Board Member 84 2021-08-31
Director/Board Member 75 2021-08-31
Date Insider Type Main position Quantity % Market Cap.
04-30
Suvretta Capital Management LLC
FreeCompany 300,000 0.8034%
02-04
Longitude Capital Management Co LLC
ConversionCompany 8,232,746 -
02-03
Suvretta Capital Management LLC
OtherCompany 3,886,317 -
Change 5-day change 1-year change 3-year change Capi.($)
-4.25%-2.02% - - 5.22B
-2.33%-0.96%+50.33%+162.29% 1,085B
-0.82%-0.91%+62.97%+61.11% 624B
-0.73%-2.62%+27.22%+84.46% 442B
+0.33%-1.43%+29.46%+26.92% 332B
-0.02%-2.92%+27.40%+46.37% 282B
-3.89%-11.72%+23.86%+26.94% 277B
+0.66%-2.94%-27.27%-39.99% 217B
-0.06%-0.83%+20.98%+61.70% 196B
-3.72%+0.17%+13.35%+71.53% 167B
Average -1.48%-2.05%+25.37%+55.70% 362.72B
Weighted average by Cap. -1.34%-1.06%+36.02%+81.84%

Financials

2026 *2027 *
Net sales - 10.39M 9.1M 8.39M 7.75M 14.7M 991M 14.95M 100M 39.27M 488M 39M 38.16M 1.68B
Net income -110M -96.18M -88.68M -81.94M -155M -10.47B -158M -1.06B -415M -5.16B -412M -403M -17.75B -117M -102M -94.41M -87.24M -165M -11.15B -168M -1.13B -442M -5.49B -439M -429M -18.9B
Net Debt - -
Logo Veradermics, Incorporated
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Employees
24
Date Price Change Volume
26-07-09 US$124.91 +5.63% 315,684
26-07-08 US$118.25 +1.24% 373,346
26-07-07 US$116.80 -4.32% 385,413
26-07-06 US$122.07 -5.91% 542,619
26-07-02 US$129.74 +0.98% 582,501
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
124.91USD
Average target price
141.60USD
Spread / Average Target
+13.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MANE Stock